These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 35025707)

  • 41. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
    Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
    Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia.
    Kosmas CE; Muñoz Estrella A; Sourlas A; Silverio D; Hilario E; Montan PD; Guzman E
    Diseases; 2018 Jul; 6(3):. PubMed ID: 30011788
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential.
    Kosmas CE; Muñoz Estrella A; Skavdis A; Peña Genao E; Martinez I; Guzman E
    Ther Clin Risk Manag; 2020; 16():1031-1037. PubMed ID: 33149595
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inclisiran, the billion-dollar drug, to lower LDL cholesterol - is it worth it?
    Doggrell SA
    Expert Opin Pharmacother; 2020 Nov; 21(16):1971-1974. PubMed ID: 32749892
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial.
    Ray KK; Stoekenbroek RM; Kallend D; Nishikido T; Leiter LA; Landmesser U; Wright RS; Wijngaard PLJ; Kastelein JJP
    JAMA Cardiol; 2019 Nov; 4(11):1067-1075. PubMed ID: 31553410
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of current and emerging treatments for hypercholesterolemia.
    Tomlinson B; Chan P; Zhang Y; Liu Z; Lam CWK
    Expert Opin Drug Metab Toxicol; 2020 May; 16(5):371-385. PubMed ID: 32223657
    [No Abstract]   [Full Text] [Related]  

  • 48. Evaluation of the distribution and excretion of [
    Lehoux D; Far AR; Kallend D; Wijngaard PLJ; Zerler B
    Toxicol Appl Pharmacol; 2022 May; 443():115978. PubMed ID: 35288146
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events.
    Turgeon RD; Pearson GJ
    Am J Health Syst Pharm; 2018 Jun; 75(11):747-754. PubMed ID: 29802110
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy.
    Board C; Kelly MS; Shapiro MD; Dixon DL
    J Cardiovasc Pharmacol; 2020 May; 75(5):410-420. PubMed ID: 32379108
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic.
    Chiou TT; Tomasi K; Taub PR; Wilkinson MJ
    J Clin Lipidol; 2023; 17(1):73-77. PubMed ID: 36371372
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New Pharmacological Approaches to Target PCSK9.
    Catapano AL; Pirillo A; Norata GD
    Curr Atheroscler Rep; 2020 Jun; 22(7):24. PubMed ID: 32495301
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inclisiran-A Revolutionary Addition to a Cholesterol-Lowering Therapy.
    Dec A; Niemiec A; Wojciechowska E; Maligłówka M; Bułdak Ł; Bołdys A; Okopień B
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047830
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy.
    Tomlinson B; Chan P; Zhang Y; Lam CWK
    Expert Opin Pharmacother; 2020 Dec; 21(17):2137-2151. PubMed ID: 32772741
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
    Polychronopoulos G; Tziomalos K
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
    Okere AN; Serra C
    Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia.
    Reijman MD; Schweizer A; Peterson ALH; Bruckert E; Stratz C; Defesche JC; Hegele RA; Wiegman A
    Eur J Prev Cardiol; 2022 Jul; 29(9):1361-1368. PubMed ID: 35175352
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials.
    Mu G; Xiang Q; Zhou S; Liu Z; Qi L; Jiang J; Gong Y; Xie Q; Wang Z; Zhang H; Huo Y; Cui Y
    Adv Ther; 2020 Apr; 37(4):1496-1521. PubMed ID: 32108309
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology.
    Mahmood T; Shapiro MD
    Curr Opin Cardiol; 2019 Sep; 34(5):519-525. PubMed ID: 31246589
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Proprotein Convertase Subtilisin Kexin 9 Inhibitors.
    Pirillo A; Catapano AL
    Cardiol Clin; 2018 May; 36(2):241-256. PubMed ID: 29609754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.